BRIEF-Bayer seeks EU approval for regorafenib for use against GIST

FRANKFURT, Sept 5 Thu Sep 5, 2013 2:37am EDT

FRANKFURT, Sept 5 (Reuters) - Bayer AG : * Says regorafenib (Stivarga) submitted for European marketing authorization

for the treatment of gastrointestinal stromal tumors (GIST).